for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bellicum Pharmaceuticals Inc

BLCM.OQ

Latest Trade

1.14USD

Change

0.04(+3.64%)

Volume

273,438

Today's Range

1.09

 - 

1.15

52 Week Range

0.91

 - 

6.64

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.10
Open
1.09
Volume
273,438
3M AVG Volume
17.55
Today's High
1.15
Today's Low
1.09
52 Week High
6.64
52 Week Low
0.91
Shares Out (MIL)
46.25
Market Cap (MIL)
50.88
Forward P/E
-0.51
Dividend (Yield %)
--

Next Event

Bellicum Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Bellicum Pharmaceuticals Announces Proposed $53 Mln Public Offering Of Preferred Stock And Warrants With Concurrent Private Placement

Bellicum Pharmaceuticals Reports Q2 2019 Results

Bellicum Pharmaceuticals Inc Files For Mixed Shelf Of Upto $400 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

Industry

Biotechnology & Drugs

Contact Info

2130 W Holcombe Blvd Ste 800

+1.832.3841100

http://www.bellicum.com/

Executive Leadership

James Farrell Brown

Independent Chairman of the Board

Richard A. Fair

President, Chief Executive Officer, Director

Atabak Mokari

Chief Financial Officer, Senior Vice President and Principal Financial Officer

Alan K. Smith

Executive Vice President of Technical Operations

Aaron A. Foster

Senior Vice President, Head of Research

Key Stats

1.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.570

2017

-2.840

2018

-2.440

2019(E)

-2.170
Price To Earnings (TTM)
--
Price To Sales (TTM)
20.26
Price To Book (MRQ)
1.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
144.26
LT Debt To Equity (MRQ)
123.04
Return on Investment (TTM)
-94.42
Return on Equity (TTM)
-81.30

Latest News

BRIEF-Bellicum Pharmaceuticals Reports Q1 Loss Per Share Of $0.68

* BELLICUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Bellicum Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* BELLICUM PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bellicum Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* BELLICUM PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Bellicum Announces Clinical Hold Lifted On U.S. Studies Of BPX-501

* BELLICUM ANNOUNCES CLINICAL HOLD LIFTED ON U.S. STUDIES OF BPX-501

BRIEF-Bellicum Pharmaceuticals Reports Qtrly Loss Per Share $0.66

* BELLICUM PHARMACEUTICALS PROVIDES OPERATIONAL UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017

BRIEF-Bellicum Announces Interim Results Showing Low Rates Of Cancer Recurrence In Pediatric AML Patients Treated With BPX-501

* BELLICUM ANNOUNCES INTERIM RESULTS SHOWING LOW RATES OF CANCER RECURRENCE IN PEDIATRIC AML PATIENTS TREATED WITH BPX-501

BRIEF-Bellicum Pharma Says Effective Feb 20, Board Approved Increase In Size Of Board To 8 Members

* BELLICUM PHARMA SAYS EFFECTIVE FEB 20, BOARD APPROVED INCREASE IN SIZE OF BOARD TO 8 MEMBERS - SEC FILING Source text: (http://bit.ly/2BMB6hN) Further company coverage:

BRIEF-Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies

* BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501 STUDIES

Bellicum's cancer drug trials on clinical hold, shares tumble

Bellicum Pharmaceuticals Inc said the U.S. Food and Drug Administration had placed a clinical hold on U.S. trials of the company's experimental cancer drug after three cases of brain disease linked to head trauma.

BRIEF-Bellicum Pharmaceuticals Announces Clinical Hold On BPX-501 Clinical Trials In U.S.

* BELLICUM PHARMACEUTICALS ANNOUNCES CLINICAL HOLD ON BPX-501 CLINICAL TRIALS IN THE UNITED STATES

BRIEF-Bellicum Enters Into Agreement With Oxford Finance To Borrow $35 Mln - SEC Filing

* BELLICUM PHARMACEUTICALS SAYS ENTERED INTO AGREEMENT WITH OXFORD FINANCE LLC TO BORROW $35.0 MILLION IN A SINGLE TERM LOAN - SEC FILING Source text: (http://bit.ly/2BhY3X0) Further company coverage:

BRIEF-Bellicum reports qtrly earnings per share loss‍ $0.71​

* Bellicum Pharmaceuticals Inc qtrly earnings per share loss $0.71

BRIEF-Bellicum Pharmaceuticals enters a cancer research grant contract with cancer prevention and research institute of Texas

* Bellicum Pharmaceuticals says on Aug. 9, entered a cancer research grant contract with cancer prevention and research institute of Texas

BRIEF-Bellicum Pharmaceuticals qtrly loss per share $0.74

* Bellicum pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Bellicum Pharmaceuticals files for mixed shelf offering of upto $150 mln

* Bellicum Pharmaceuticals Inc files for mixed shelf offering of upto $150 million - sec filing Source text: (http://bit.ly/2tmwwmp) Further company coverage:

BRIEF-Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares

* Bellicum Pharmaceuticals files prospectus relating to disposition of up to about 5 million shares of co's common stock held by the selling stockholders

BRIEF-Bellicum Pharmaceuticals qtrly loss per share $0.80

* Bellicum pharmaceuticals reports first quarter 2017 financial results

BRIEF-Bellicum Pharmaceuticals says public offering of 5 mln shares priced at $12 each

* Bellicum Pharmaceuticals announces pricing of public offering of common stock

BRIEF-Bellicum Pharmaceuticals announces proposed public offering of 5 mln common stock

* Bellicum Pharmaceuticals announces proposed public offering of common stock

BRIEF-Bellicum Pharmaceuticals posts Q4 net loss $19.9 mln

* Bellicum Pharmaceuticals provides operational update and reports financial results for the fourth quarter and year ended December 31, 2016

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up